Stoçk has Goné from 3.50 to 24.70 in past few months with excellent P1 results in GLP-1 drug for weight loss and diabetes. Viking looking to advance the drug into a P1 weight loss trial. GLP-1 are all the rage for diabetes and weight loss i.e Ozempic and Mounjaro among several GLP-1 drugs Being advertised 24/7. Always room for a good oral in any indication i.e Etrasimod from Arena.

Viking released excellent safety and efficacy P2b trial data today for NASH. Drug is given subcutaneously. This is a very difficult indication yet Viking drug showed exceptional in the P2b trial released today.

San Diego is hometown of Arena so thought there might be some familiarity with Viking by some posters on this board.

I bought 1451 shares today and considering buying more. Any insight appreciated.


Tia